Xenetic Biosciences Q3 2026 net loss more than triples to $1.7 million

• Xenetic Biosciences’ third-quarter 2026 net loss more than tripled year over year to approximately $1.7 million.
• Royalty revenue fell 29% to approximately $700,000, primarily due to positive royalty adjustments recognized in the prior-year quarter.
• General and administrative expenses more than doubled to approximately $1.9 million, primarily due to higher transaction-related legal and financial advisory expenses.
• The proposed all-stock acquisition of Santersus is expected to close in the first quarter of 2027, subject to stockholder approval and other conditions.
• A Phase I study combining DNase I with CAR T-cell therapy dosed its first patient; initial efficacy data are expected in second-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611130830ACCESSWRNAPR_____1250890) on November 13, 2026, and is solely responsible for the information contained therein.